decorative image
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
decorative image
Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

n/a Warning! This browser is not supported - Some features might not work. Try using a different browser such as Chrome, Edge, Firefox, or Safari.

Update to NIH Management of Genomic Summary Results Access

To maximize public benefit from genomic information generated through NIH-supported research in a manner consistent with current scientific and ethical considerations, and to promote of scientific advances while protecting research participants’ privacy interests, NIH is updating its data management procedures under the Genomic Data Sharing Policy to allow unrestricted access to genomic summary results from most NIH-supported studies for health or research purposes.

Publication of the Revised NIH Grants Policy Statement (NIHGPS) for FY 2019

The revised NIHGPS is applicable to all NIH grants and cooperative agreements with budget periods beginning on or after October 1, 2018. This revision supersedes October 2017 GPS as a standard term and condition of award.  Previous versions of the NIHGPS remain applicable as a standard term and condition for all NIH grants and cooperative agreements with budget periods that began prior to October 1, 2018. See NOT-OD-19-021.
 

Responsibilities of Recipient Institutions in Communicating Research Misconduct to the NIH

A reminder that if a recipient institution initiates a research misconduct investigation, it must take any necessary steps to:
  • protect the scientific integrity of the project;
  • protect human participants, live vertebrate animals and the environment;
  • ensure the proper expenditure of funds and, if appropriate, continuation of the project during the investigation; and
  • provide reports to the HHS Office of Research Integrity
 

Reinstatement of NIH SBIR Direct-to-Phase II Authority and Associated Updates to NIH SBIR Omnibus Solicitations

A ‘Direct-to-Phase II’ SBIR award is a Phase II award issued to a small business that did not receive a Phase I award for that research/research & development. Recent legislation has re-instated this SBIR Direct Phase II provision through Fiscal Year 2022 and NIH is re-implementing the SBIR Direct-to-Phase II program. The prior program had specific SBIR Direct-to-Phase II funding opportunity announcements (FOAs). These will not be needed now.